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Lung cancer is the most common cancer with over 1.3 million incident 
cases per year, lung cancer has the highest worldwide rate of cancer 
mortality (1). More than half of all cases are diagnosed at an advanced 
stage when surgical removal is no longer a viable treatment strategy. As 
a result, the overall 5-year survival rate is low, but stage-speciﬁc sur-
vival rates differ substantially by stage at presentation. This raises the 
possibility that lung cancer may be an attractive candidate for screen-
ing, to detect disease at an early stage when treatment would be more 
effective. Recent results from the International Early Lung Cancer 
Action Program (I-ELCAP) would appear to support this argument (2). 
However, whilst the I-ELCAP results are very encouraging, there are 
also potential negative consequences of screening, including screen-de-
tected false positives. The positive predictive value of spiral CT is usu-
ally 10% or less when applied to a population with a disease prevalence 
of 2-3%. A screening test with a low positive predictive value generates 
greater costs without corresponding beneﬁts and may even cause harm 
to the participants. A more precise deﬁnition of risk would enable one 
to choose a target population with increased disease prevalence and 
hence improve the positive predictive value of CT detected abnor-
mality. Therefore, central to the development of a cost-effective lung 
cancer early detection strategy using spiral CT is the ability to identify 
individuals at the highest risk for lung cancer. Previous lung cancer risk 
prediction models have been based on smoking and age. Using these 
and additional lifestyle risk factors, we have developed the Liverpool 
Lung Project (LLP) Risk Model to calculate an individual’s absolute 
risk for lung cancer within a 5-year period. 
The case-control data used to develop the LLP Risk Model were de-
rived from an ongoing molecular-epidemiological study of lung cancer 
in Liverpool (3), The Liverpool Lung Project (LLP), of which 579 
cases and 1159 controls were used in this analysis. Each potential risk 
factor for lung cancer was examined ﬁrst by conditional logistic regres-
sion and only statistically signiﬁcant covariates (p<0.05) were included 
in the multivariate model. Signiﬁcant risk factors include smoking 
duration, family history of lung cancer (4), history of non-pulmonary 
malignant tumour, history of pneumonia and occupational exposure to 
asbestos. The components used to project absolute risk of lung cancer 
over a deﬁned period were the relative risk model, the baseline inci-
dence rate for lung cancer and the corresponding risk of mortality from 
non-lung cancer causes. 
Risk Scenarios (Percentage risk,): (i) Male, 60y, Family history not<60, 
40y smoking (3.6); Male 60y, (ii) Family history not <60y, Never-smoker 
(0.3); (iii) Male 60y, 40 y smoking (3.0); (iv) Male 60y, Family history 
<60y, 40y smoking, asbestosis exposure, Pneumonia, Previous other 
malignancy (30); (iiv) Male 60 years Family history <60y, Never smoker, 
& Asbestosis exposure, Pneumonia, Previous other malignancy (3.3).
In comparison with previous lung cancer prediction models, the LLP 
risk model has distinctive strengths. First the predictor variables are 
all explicitly deﬁned and can be readily assessed at the time of patient 
presentation. Second, patients can be assigned to their appropriate risk 
class on the basis of information from the initial history alone. The LLP 
Risk Model will require rigorous validation in a separate population. 
Methylation biomarkers in sputum specimens are now considered as 
one of the most important tools in early lung cancer research (5). In 
collaboration with Sequenom, the LLP research group have character-
ised DNA methylation status in NSCLC normal and tumour specimens 
using MALDI-TOF Mass Spectrometry (6). We evaluated the predic-
tive power of the data and applied a tree based classiﬁcation algorithm. 
After matching individuals for age, sex and histology, we divided the 
data into test and validation series. The J48 methods of the WEKA 
package, a java re-implementation of the C4.5 algorithm, were used. 
On completion, the model was evaluated on the validation series. This 
yielded a 90% classiﬁcation accuracy with high sensitivity (96%) and 
speciﬁcity (97%). We concluded that the methylation proﬁles of 5 
speciﬁc genes constitutes an excellent tool to identify discriminatory 
methylation markers for population-based lung cancer screening (7). 
We have recently demonstrated the importance of gene silencing of the 
CYGB gene in NSCLC (8).
The utilisation of the LLP Risk Model together with patient stratiﬁca-
tion by lung function test, cytology and methylation proﬁling has been 
set up as a feasibility study in the Primary Care setting to facilitate 
the referral of high risk individuals for bronchoscopic and spiral CT 
investigations for lung cancer early detection. Thus, the implementation 
of the lung cancer risk prediction model together with known clinical 
variables and methylation is currently being tested to ascertain if high 
risk patients can be identiﬁed, will provide a potential methodology for 
selecting individuals for future screening programmes (9).
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